Rifaximin for preventing episodes of overt hepatic encephalopathy

  • Technology appraisal guidance
  • TA337
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older.